- Home
- DEA vs ZYME Comparison
DEA vs ZYME Comparison
Compare DEA & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEA
- ZYME
- Stock Information
- Founded
- DEA 2011
- ZYME 2003
- Country
- DEA United States
- ZYME United States
- Employees
- DEA N/A
- ZYME N/A
- Industry
- DEA Real Estate Investment Trusts
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- DEA Real Estate
- ZYME Health Care
- Exchange
- DEA Nasdaq
- ZYME Nasdaq
- Market Cap
- DEA 912.0M
- ZYME 867.6M
- IPO Year
- DEA 2015
- ZYME 2017
- Fundamental
- Price
- DEA $22.11
- ZYME $12.47
- Analyst Decision
- DEA Hold
- ZYME Buy
- Analyst Count
- DEA 4
- ZYME 7
- Target Price
- DEA $27.69
- ZYME $19.50
- AVG Volume (30 Days)
- DEA 519.1K
- ZYME 499.3K
- Earning Date
- DEA 07-30-2025
- ZYME 07-31-2025
- Dividend Yield
- DEA 8.13%
- ZYME N/A
- EPS Growth
- DEA N/A
- ZYME N/A
- EPS
- DEA 0.41
- ZYME N/A
- Revenue
- DEA $314,385,000.00
- ZYME $93,384,000.00
- Revenue This Year
- DEA $7.80
- ZYME $44.71
- Revenue Next Year
- DEA $8.44
- ZYME $34.57
- P/E Ratio
- DEA $54.19
- ZYME N/A
- Revenue Growth
- DEA 6.82
- ZYME 85.05
- 52 Week Low
- DEA $19.33
- ZYME $8.32
- 52 Week High
- DEA $36.31
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- DEA 51.08
- ZYME 51.94
- Support Level
- DEA $21.79
- ZYME $12.06
- Resistance Level
- DEA $22.88
- ZYME $12.90
- Average True Range (ATR)
- DEA 0.54
- ZYME 0.52
- MACD
- DEA -0.08
- ZYME -0.03
- Stochastic Oscillator
- DEA 32.26
- ZYME 29.66
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.